Trial Profile

A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Arsenic trioxide (Primary) ; Cytarabine; Idarubicin; Mercaptopurine; Methotrexate; Methotrexate; Mitoxantrone; Tretinoin
Indications Acute promyelocytic leukaemia
Focus Therapeutic Use
Acronyms APOLLO

26 Feb 2025 Status changed from active, no longer recruiting to completed.
04 Aug 2022 Planned End Date changed from 1 Mar 2025 to 1 Jan 2025.
04 Aug 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com